Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
about
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids.Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats.A Trishistidine Pseudopeptide with Ability to Remove Both CuΙ and CuΙΙ from the Amyloid-β Peptide and to Stop the Associated ROS Formation.Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future.Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.Pro-neurogenic, Memory-Enhancing and Anti-stress Effects of DF302, a Novel Fluorine Gamma-Carboline Derivative with Multi-target Mechanism of Action.β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View.Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.Association between SORL1 polymorphisms and the risk of Alzheimer's disease.Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.Binding Modes of Phthalocyanines to Amyloid β Peptide and Their Effects on Amyloid Fibril Formation.Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins
P2860
Q38659874-1CC6F39D-D285-456E-89E3-4EE281949247Q38669030-6F30A987-4829-41C0-8D7B-C0D8AC9D84E5Q42293352-B9A7C1DF-19CF-4C79-8BBD-15565D7C5A37Q46231560-D9041DBC-FB32-4E09-82C5-C15C9ED58917Q46315694-9233F96D-AD83-40D9-B8FF-E29A4849A983Q47134297-FE43AABD-6B32-4E82-945A-2CB2CAA6CCD0Q47396500-2978324D-A8D5-4D83-87AE-55A121458C9BQ47552991-CDDCCDB1-4408-4E68-BCAA-FA44B7176D38Q47633396-F9A926AA-C03E-4A3C-9A76-F77B010FFA67Q47672665-CFCAFB16-805D-46AD-9C45-D44131D631F7Q47780004-EE3E1BAC-8AB0-40C0-BFAC-1EAFD34F46FAQ47784277-FEFEBAB6-1FD6-4960-BBDF-F4DFEB0B43A1Q51762778-149EA707-4073-4891-A866-6CCFEA7DDBEFQ52355802-D350F8AC-BF77-46A5-BBEC-66372928E8FEQ54940167-9C1472EF-6DBA-4909-8C70-508824A4E79BQ56999539-FEF649C9-53A1-4FB9-BBB0-13F98AD1FD6F
P2860
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@en
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@nl
type
label
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@en
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@nl
prefLabel
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@en
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@nl
P2860
P356
P1476
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
@en
P2093
Elena V Bovina
Sergey O Bachurin
P2860
P304
P356
10.1002/MED.21434
P577
2017-01-13T00:00:00Z